(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 4.03% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.95%.
Zoetis's revenue in 2026 is $9,509,000,000.On average, 21 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,129,396,962,300, with the lowest ZTS revenue forecast at $3,979,313,296,056, and the highest ZTS revenue forecast at $4,366,680,077,088. On average, 21 Wall Street analysts forecast ZTS's revenue for 2027 to be $4,289,961,331,494, with the lowest ZTS revenue forecast at $4,086,635,694,264, and the highest ZTS revenue forecast at $4,632,889,932,018.
In 2028, ZTS is forecast to generate $4,497,060,021,786 in revenue, with the lowest revenue forecast at $4,197,311,917,416 and the highest revenue forecast at $4,877,299,924,812.